TY  - GEN
AU  - Di Minno, Giovanni
AU  - Navarro, David
AU  - Perno, Carlo Federico
AU  - Canaro Hirnyk, Mariana
AU  - Guertler, Lutz
AU  - Ironside, James W
AU  - Eichler, Hermann
AU  - Tiede, Andreas
PY  - 2017
DO  - 10.1007/s00277-017-3028-4
SN  - 0939-5555
UR  - http://hdl.handle.net/20.500.12105/20491
AB  - Patients with blood disorders (including leukaemia, platelet function disorders and coagulation factor deficiencies) or acute bleeding receive blood-derived products, such as red blood cells, platelet concentrates and plasma-derived products. Although...
LA  - eng
PB  - Springer
KW  - Pathogen
KW  - Inactivation
KW  - Virus
KW  - Removal
KW  - Blood
KW  - Clotting
KW  - Bleeding disorder
KW  - Infection risk
KW  - Patient information
KW  - Blood Coagulation Disorders
KW  - Hemorrhagic Disorders
KW  - Blood Safety
KW  - Blood Transfusion
KW  - Blood-Borne Pathogens
KW  - Risk Assessment
KW  - Risk Factors
KW  - Sepsis
KW  - Disinfection
KW  - Humans
TI  - Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
TY  - review article
ER  -